Revenue
2018
2019
2020
2021
2022
2023
2024
2025
X4 Pharmaceuticals, Inc (XFOR)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.1M | $2.6M | $0 | $0 | $0 | $3.0M | $0 | $0 | — | — |
| Research & development | $72.7M | $81.6M | $72.0M | $61.1M | $50.6M | $41.9M | $30.2M | $20.3M | $17.1M | $17.8M |
| Operating expenses | — | — | $107.5M | $87.6M | $85.1M | $62.9M | $51.7M | $29.1M | $22.2M | $24.3M |
| Operating income | −$86.9M | −$36.4M | −$107.5M | −$87.6M | −$85.1M | −$59.9M | −$51.7M | −$29.1M | −$22.2M | −$24.3M |
| EBITDAderived | −$85.6M | −$35.6M | −$107.1M | −$87.1M | −$84.6M | −$59.5M | −$51.6M | −$29.0M | −$22.2M | −$24.1M |
| Net income | −$79.2M | −$37.5M | −$101.2M | −$93.9M | −$88.7M | −$62.1M | −$52.8M | −$33.3M | −$22.0M | −$23.0M |
| Basic EPSper diluted share | -$1.87 | -$5.59 | -$17.07 | -$1.52 | -$3.99 | -$3.09 | -$4.63 | -$79.15 | -$54.58 | -$44.79 |
| Diluted EPSper diluted share | -$1.87 | -$5.59 | -$17.07 | -$1.52 | -$3.99 | -$3.09 | -$4.63 | -$79.15 | -$54.58 | -$44.79 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 12, 2026Form 4 | KIRSKE DAVIDChief Financial Officer | SellCommon Stock | 17.0K | $4.29 | $72.8K | 176.3K |
| Oct 23, 2025Form 4 | Craig Adam RExecutive Chairman | BuyCommon Stock | 86.2K | $2.90 | $250.0K | 376.1K |
| May 16, 2025Form 4 | Baldry MarkChief Commercial Officer | BuyCommon Stock | 1.0K | $2.48 | $2.6K | 25.3K |
| Jan 24, 2025Form 4 | Ragan PaulaPresident and CEO | SellCommon Stock | 76.5K | $0.45 | $34.4K | 1.09M |
| Jan 24, 2025Form 4 | Mostafa Adam S.Chief Financial Officer | SellCommon Stock | 74.8K | $0.45 | $33.6K | 0 |